Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
X4 Pharmaceuticals Inc
XFORCurrent price
0.34 USD
+0.013 USD (+4.07%)
Last closed
0.32 USD
Company
www.x4pharma.com
ISIN
US98420X1037
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
110 002 168 USD
Yield for 12 month
-63.34 %
1Y
3Y
5Y
10Y
15Y
XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. Address: 61 North Beacon Street, Boston, MA, United States, 02134
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.68 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
+560 000 USD
Last Quarter
+563 000 USD
Current Year
-1 996 000 USD
Last Year
-1 994 000 USD
Current Quarter
+333 000 USD
Last Quarter
+295 000 USD
Key Figures XFOR
1 year
3 years
5 years
10 years
EBITDA
-123 177 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-40.23 %
PEG Ratio
–
Return On Equity TTM
21.77 %
Wall Street Target Price
2.68 USD
Revenue TTM
563 000 USD
Book Value
0.31 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
3 000 000 USD
Earnings per share
-0.080 USD
Diluted Eps TTM
-0.080 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
3 131.79 %
Dividend Analytics XFOR
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History XFOR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
14.03.2019
Stock Valuation XFOR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
47.40
Price Sales TTM
195.39
Enterprise Value EBITDA
1.10
Price Book MRQ
1.85
Financials XFOR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators XFOR
For 52 weeks
0.26 USD
1.60 USD
50 Day MA
0.49 USD
Shares Short Prior Month
12 938 054
200 Day MA
0.81 USD
Short Ratio
8.64
Shares Short
12 501 447
Short Percent
6.84 %
BeatStart